FOXA1

FOXA1
Identifiers
AliasesFOXA1, HNF3A, TCF3A, forkhead box A1
External IDsMGI: 1347472 HomoloGene: 3307 GeneCards: FOXA1
Gene location (Human)
Chr.Chromosome 14 (human)[1]
Band14q21.1Start37,589,984 bp[1]
End37,596,059 bp[1]
Orthologs
SpeciesHumanMouse
Entrez

3169

15375

Ensembl

ENSG00000129514

ENSMUSG00000035451

UniProt

P55317

P35582

RefSeq (mRNA)

NM_004496

NM_008259

RefSeq (protein)

NP_004487

NP_032285

Location (UCSC)Chr 14: 37.59 – 37.6 MbChr 12: 57.54 – 57.55 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Forkhead box protein A1 (FOXA1), also known as hepatocyte nuclear factor 3-alpha (HNF-3A), is a protein that in humans is encoded by the FOXA1 gene.[5][6][7]

Function

FOXA1 is a member of the forkhead class of DNA-binding proteins. These hepatocyte nuclear factors are transcriptional activators for liver-specific transcripts such as albumin and transthyretin, and they also interact with chromatin as a pioneer factor. Similar family members in mice have roles in the regulation of metabolism and in the differentiation of the pancreas and liver.[5]

Marker in breast cancer

FOXA1 in breast cancer is highly correlated with ERα+, GATA3+, and PR+ protein expression as well as endocrine signaling. FOXA1 acts as a pioneer factor for ERa in ERα+ breast cancer, and its expression might identify ERα+ cancers that undergo rapid reprogramming of ERa signaling that is associated with poor outcomes and treatment resistance.[8] Conversely, in ERα− breast cancer FOXA1 is highly correlated with low-grade morphology and improved disease free survival. FOXA1 is a downstream target of GATA3 in the mammary gland.[9] Expression in ERα− cancers may identify a subset of tumors that is responsive to other endocrine therapies such as androgen receptor antagonist treatment.[10][11]

Role in prostate cancer

Mutations in this gene have been recurrently seen in instances of prostate cancer.[12]

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000129514 - Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000035451 - Ensembl, May 2017
  3. ↑ "Human PubMed Reference:".
  4. ↑ "Mouse PubMed Reference:".
  5. 1 2 "Entrez Gene: forkhead box A1".
  6. ↑ Bingle CD, Gowan S (1996). "Molecular cloning of the forkhead transcription factor HNF-3 alpha from a human pulmonary adenocarcinoma cell line". Biochim Biophys Acta. 1307 (1): 17–20. doi:10.1016/0167-4781(96)00058-9. PMID 8652662.
  7. ↑ Mincheva A, Lichter P, Schütz G, Kaestner KH (1997). "Assignment of the human genes for hepatocyte nuclear factor 3-alpha, -beta, and -gamma (HNF3A, HNF3B, HNF3G) to 14q12-q13, 20p11, and 19q13.2-q13.4". Genomics. 39 (3): 417–9. doi:10.1006/geno.1996.4477. PMID 9119385.
  8. ↑ Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin SF, Palmieri C, Caldas C, Carroll JS (4 January 2012). "Differential oestrogen receptor binding is associated with clinical outcome in breast cancer". Nature. 481 (7381): 389–93. doi:10.1038/nature10730. PMC 3272464. PMID 22217937.
  9. ↑ Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z (December 2006). "GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland". Cell. 127 (5): 1041–55. doi:10.1016/j.cell.2006.09.048. PMC 2646406. PMID 17129787.
  10. ↑ Albergaria A, Paredes J, Sousa B, Milanezi F, Carneiro V, Bastos J, Costa S, Vieira D, Lopes N, Lam EW, Lunet N, Schmitt F (2009). "Expression of FOXA1 and GATA-3 in breast cancer: The prognostic significance in hormone receptor-negative tumours". Breast Cancer Research. 11 (3): R40. doi:10.1186/bcr2327. PMC 2716509. PMID 19549328.
  11. ↑ Sanga S, Broom BM, Cristini V, Edgerton ME (2009). "Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family". BMC Medical Genomics. 2: 59. doi:10.1186/1755-8794-2-59. PMC 2753593. PMID 19747394.
  12. ↑ Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, Park K, Kitabayashi N, MacDonald TY, Sheikh K, Vuong T, Guiducci C, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Hussain WM, Ramos AH, Winckler W, Redman MC, Ardlie K, Tewari AK, Mosquera JM, Rupp N, Wild PJ, Moch H, Morrissey C, Nelson PS, Kantoff PW, Gabriel SB, Golub TR, Meyerson M, Lander ES, Getz G, Rubin MA, Garraway LA (June 2012). "Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer". Nat. Genet. 44 (6): 685–9. doi:10.1038/ng.2279. PMC 3673022. PMID 22610119.

Further reading

  • Song L, Xu Z, Zhang C, et al. (2009). "Up-regulation of the HSP72 by Foxa1 in MCF-7 human breast cancer cell line". Biochem. Biophys. Res. Commun. 386 (1): 30–4. doi:10.1016/j.bbrc.2009.05.120. PMID 19486887.
  • Zhang Y, Ali TZ, Zhou H, et al. (2010). "ErbB3 binding protein 1 represses metastasis-promoting gene anterior gradient protein 2 in prostate cancer". Cancer Res. 70 (1): 240–8. doi:10.1158/0008-5472.CAN-09-2904. PMC 3724404. PMID 20048076.
  • McMullin RP, Dobi A, Mutton LN, et al. (2010). "A FOXA1-binding enhancer regulates Hoxb13 expression in the prostate gland". Proc. Natl. Acad. Sci. U.S.A. 107 (1): 98–103. doi:10.1073/pnas.0902001107. PMC 2806740. PMID 20018680.
  • Sun Q, Yu X, Degraff DJ, Matusik RJ (2009). "Upstream stimulatory factor 2, a novel FoxA1-interacting protein, is involved in prostate-specific gene expression". Mol. Endocrinol. 23 (12): 2038–47. doi:10.1210/me.2009-0092. PMC 2796152. PMID 19846536.
  • Liu N, Niu Y, Wang SL, et al. (2010). "[Diagnostic and prognostic significance of FOXA1 expression in molecular subtypes of breast invasive ductal carcinomas]". Zhonghua Yi Xue Za Zhi. 90 (20): 1403–7. PMID 20646630.
  • Haiman CA, Garcia RR, Hsu C, et al. (2009). "Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort". BMC Cancer. 9: 43. doi:10.1186/1471-2407-9-43. PMC 2637888. PMID 19183483.
  • Kohler S, Cirillo LA (2010). "Stable chromatin binding prevents FoxA acetylation, preserving FoxA chromatin remodeling". J. Biol. Chem. 285 (1): 464–72. doi:10.1074/jbc.M109.063149. PMC 2804194. PMID 19897491.
  • Malik S, Jiang S, Garee JP, et al. (2010). "Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM". Mol. Cell. Biol. 30 (2): 399–412. doi:10.1128/MCB.00907-09. PMC 2798473. PMID 19917725.
  • Motallebipour M, Ameur A, Reddy Bysani MS, et al. (2009). "Differential binding and co-binding pattern of FOXA1 and FOXA3 and their relation to H3K4me3 in HepG2 cells revealed by ChIP-seq". Genome Biol. 10 (11): R129. doi:10.1186/gb-2009-10-11-r129. PMC 3091322. PMID 19919681.
  • Eeckhoute J, Lupien M, Meyer CA, et al. (2009). "Cell-type selective chromatin remodeling defines the active subset of FOXA1-bound enhancers". Genome Res. 19 (3): 372–80. doi:10.1101/gr.084582.108. PMC 2661808. PMID 19129543.
  • Nakshatri H, Badve S (2007). "FOXA1 as a therapeutic target for breast cancer". Expert Opin. Ther. Targets. 11 (4): 507–14. doi:10.1517/14728222.11.4.507. PMID 17373880.
  • Iacobazzi V, Infantino V, Bisaccia F, et al. (2009). "Role of FOXA in mitochondrial citrate carrier gene expression and insulin secretion". Biochem. Biophys. Res. Commun. 385 (2): 220–4. doi:10.1016/j.bbrc.2009.05.030. PMID 19445897.
  • Nucera C, Eeckhoute J, Finn S, et al. (2009). "FOXA1 is a potential oncogene in anaplastic thyroid carcinoma". Clin. Cancer Res. 15 (11): 3680–9. doi:10.1158/1078-0432.CCR-08-3155. PMID 19470727.
  • Nakshatri H, Badve S (2009). "FOXA1 in breast cancer". Expert Rev Mol Med. 11: e8. doi:10.1017/S1462399409001008. PMID 19261198.
  • Song Y, Washington MK, Crawford HC (2010). "Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer". Cancer Res. 70 (5): 2115–25. doi:10.1158/0008-5472.CAN-09-2979. PMC 2831111. PMID 20160041.
  • Lee HJ, Chattopadhyay S, Yoon WH, et al. (2010). "Overexpression of hepatocyte nuclear factor-3alpha induces apoptosis through the upregulation and accumulation of cytoplasmic p53 in prostate cancer cells". Prostate. 70 (4): 353–61. doi:10.1002/pros.21069. PMID 19866472.
  • Bernardo GM, Lozada KL, Miedler JD, et al. (2010). "FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis". Development. 137 (12): 2045–54. doi:10.1242/dev.043299. PMC 2875844. PMID 20501593.
  • Albergaria A, Paredes J, Sousa B, et al. (2009). "Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours". Breast Cancer Res. 11 (3): R40. doi:10.1186/bcr2327. PMC 2716509. PMID 19549328.
  • Huang QY, Li GH, Kung AW (2009). "The -9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPalpha and FOXA1 binding is associated with osteoporosis". Bone. 45 (2): 289–94. doi:10.1016/j.bone.2009.03.676. PMID 19371798.
  • Sano M, Aoyagi K, Takahashi H, et al. (2010). "Forkhead box A1 transcriptional pathway in KRT7-expressing esophageal squamous cell carcinomas with extensive lymph node metastasis". Int. J. Oncol. 36 (2): 321–30. doi:10.3892/ijo_00000503. PMID 20043065.

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.